Design, Synthesis, and Biological Evaluation of Novel Heteroaryl, Squaramide, and Indolcarboxamide Derivatives as Formyl Peptide Receptor 2 Agonists to Target Neuroinflammation.
Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Fabio FrancavillaDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0009-0004-3921-7597
Daniele VitoneDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.
Igor A SchepetkinDepartment of Microbiology and Cell Biology, Montana State University, Bozeman, Montana 59717, United States.
Lilya N KirpotinaDepartment of Microbiology and Cell Biology, Montana State University, Bozeman, Montana 59717, United States.
Antonio CarrieriDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0000-0002-7725-6667
Leonardo BrunettiDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0000-0002-7787-6639
Imane Ghafir El IdrissiDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.
Maria Grazia PerroneDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0000-0003-4195-5228
Jakub Kosma FrydrychLaboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Kraków, Poland.
Ewa TrojanLaboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Kraków, Poland.
Mark T QuinnDepartment of Microbiology and Cell Biology, Montana State University, Bozeman, Montana 59717, United States.ORCID 0000-0001-8114-5073
Agnieszka Basta-KaimDepartment of Microbiology and Cell Biology, Montana State University, Bozeman, Montana 59717, United States.ORCID 0000-0002-3109-0040
Enza LacivitaDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0000-0003-2443-1174
Marcello LeopoldoDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0000-0001-8401-2815
Funding
Research Core (Developmental Research Project Program)P20GM103474 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI Ann Therese Bertagnolli · 2012 to 2026
$60.0M
NIGMS NIH HHS P20 GM103474
6 · The paper itself
Abstract
Recent research reveals Formyl Peptide Receptor 2 (FPR2) as a relevant G Protein-Coupled Receptor involved in the resolution phase of inflammation. Therefore, FPR2 agonists are promising agents to tackle neuroinflammatory-based diseases, such as Alzheimer's Disease or Autism Spectrum Disorder. Here, we describe the synthesis and biological evaluation of novel FPR2 agonists designed through the bioisosteric replacement of the phenyl urea function in the potent FPR2 agonist (S)-1-(3-(4-cyanophenyl)-1-(indolin-1-yl)-1-oxopropan-2-yl)-3-(4-fluorophenyl)urea (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Design, Synthesis, and Biological Evaluation of Novel Heteroaryl, Squaramide, and Indolcarboxamide Derivatives as Formyl Peptide Receptor 2 Agonists to Target Neuroinflammation. · full record | OpenQuestion